PMVP

$1.59+0.04 (+2.24%)

Market OpenAs of Mar 17, 6:58 PM UTC

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.59
Potential Upside
5%
Whystock Fair Value$1.67
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural c...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-55.37%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
9.89

Recent News

Motley Fool
Feb 3, 2026

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 3, 2026

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 29, 2026

Caesarstone And 2 More Penny Stocks Worth Watching

As the U.S. market faces fluctuations with major indices like the Dow Jones and S&P 500 experiencing declines, investors are increasingly seeking alternative opportunities to diversify their portfolios. Penny stocks, a term that may seem outdated, continue to hold potential for those willing to explore smaller or newer companies that can offer growth at lower price points. With strong balance sheets and solid fundamentals, these stocks can present hidden gems in today's market landscape,...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 18, 2025

Top Penny Stocks To Watch In November 2025

As the U.S. market experiences a downturn with major indexes like the Dow Jones dropping significantly, investors are seeking opportunities that can weather current uncertainties. Penny stocks, though an older term, remain relevant for those looking to invest in smaller or newer companies that might offer unique growth prospects. By focusing on penny stocks with strong financial health, investors can potentially uncover hidden gems amidst market volatility.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Oct 28, 2025

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.